INTRODUCTION
============

Schizophrenia is a mental disorder characterized by behavioral, social, and cognitive deficits with a chronic and disabling course that commonly requires life-long therapeutic intervention.[@b1-cpn-17-423],[@b2-cpn-17-423] Although atypical antipsychotics (AAP) are considered the cornerstone of schizophrenia treatment, the effect of these treatments is limited by unfavorable side effects, poor response to medication, and modest efficacy on negative symptoms.[@b3-cpn-17-423] Up to 70% of schizophrenic patients do not achieve full remission even with optimized antipsychotic treatment.[@b4-cpn-17-423] When patients fail to respond to an antipsychotic, switching to another antipsychotic agent should be considered.[@b5-cpn-17-423] However, as all antipsychotics have advantages and disadvantages, it is difficult to determine whether one is better than the others in treatment decision making, and there is still controversy regarding which antipsychotics are preferable. Previous studies have recommended that the choice of antipsychotic medication should take into account the likely benefits and possible side effects of each drug, including metabolic, extrapyramidal, cardiovascular, and hormonal side effects.[@b6-cpn-17-423]

Blonanserin is a second-generation antipsychotic commonly used in Japan and Korea with a unique pharmacological profile. It has higher dopamine D2 receptor occupancy (K~i~ = 0.142 nM) and lower serotonin 2A receptor-blocking activity (K~i~ = 0.812 nM) than those of other second-generation antipsychotic agents.[@b7-cpn-17-423] It also has weak dopamine D1 adrenergic alpha 1 receptor blocking activity.[@b8-cpn-17-423] The effectiveness of blonanserin in the treatment of schizophrenia has been demonstrated by double-blind, randomized trials,[@b9-cpn-17-423]--[@b12-cpn-17-423] a combination trial,[@b13-cpn-17-423] and a meta-analysis.[@b14-cpn-17-423] Blonanserin was found to be comparable in efficacy with other antipsychotics, according to the Positive and Negative Syndrome Scale total score; positive, negative, and general psychopathology subscale scores; and response rate.[@b14-cpn-17-423] Moreover, blonanserin is generally well tolerated with low risk of causing cardiovascular or metabolic side effects or hyperprolactinemia,[@b8-cpn-17-423] and it showed a lower rate of discontinuation due to intolerance compared with other AAPs, including quetiapine, aripiprazole, risperidone, and olanzapine.[@b15-cpn-17-423] Schizophrenia is associated with an increased risk of metabolic disorders, which can negatively influence mortality and morbidity,[@b16-cpn-17-423] and these adverse events (AEs) are among the most important reasons for switching from one antipsychotic to another[@b17-cpn-17-423],[@b18-cpn-17-423]; consequently, blonanserin may be an alternative option for patients who need to switch antipsychotic drugs due to insufficient efficacy or intolerability.

However, no studies have evaluated switching from other antipsychotics to blonanserin. The goal of this study was to test the hypothesis that switching from other antipsychotics to blonanserin will improve psychotic symptoms, and blonanserin will be well tolerated in patients who show an in sufficient response to other antipsychotics.

METHODS
=======

Study Design and Subjects
-------------------------

This was an open-label, prospective, multicenter, 12-week study that included 52 patients. This study was conducted at seven centers in Korea, consisting of six university/general hospitals and one psychiatric hospital. The patients were 20 to 60 years old and diagnosed with schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision. Subjects had been receiving one or more antipsychotics other than blonanserin at an adequate dose for more than 2 weeks before enrollment. Subjects showing an insufficient response to antipsychotics, defined as continued evidence of at least moderately severe illness (18-item Korean version of the Brief Psychiatric Rating Scale \[BPRS\] score \> 45) after a minimum of 2 weeks of treatment, were included in the study.

Patients considered being at risk of suicide or homicide and women who were pregnant, lactating, or not using a reliable form of birth control were excluded from the study. Individuals with medical conditions that could interfere with daily life activities, a diagnosis of any Axis I disorder other than schizophrenia, mental retardation, or current or a history of neurological disease were also excluded. In addition, patients treated with clozapine or long-acting injectable antipsychotics within 6 months of the study or with antidepressants, mood stabilizers, or anticonvulsants within 1 month of the study, those currently being treated with lipid-lowering medications, and those known to be resistant to treatment were excluded. All subjects provided informed consent before participation in the study.

It is recommended that blonanserin is started at 4 mg/day and dosed flexibly from 8 to 24 mg/day at the discretion of the investigator. The previously used antipsychotic agent was cross-tapered by gradually tapering during the first 2 weeks of the study period. Patients were not given any other antipsychotics, mood stabilizers/anticonvulsants, antidepressants, lipid-lowering medications, or strong CYP3A4 inhibitors during the study. Benzodiazepines could be given at doses of up to 4 mg/day to treat anxiety or agitation. Anti-parkinsonian agents and propranolol were permitted to treat extrapyramidal symptoms (EPS) or akathisia but were not to be administered prophylactically. Hypnotics other than trazodone were permitted at the discretion of the investigator.

Measurements
------------

Efficacy was evaluated at baseline and at weeks 1, 2, 4, 8, and 12. The primary assessment of efficacy was the mean change in the BPRS total score from baseline to week 12. Additional efficacy measures included mean changes in the Clinical Global Impression-Severity score and each item score on the BPRS, and the response rate evaluated using the BPRS. Response was defined as a ≥ 30% decrease in the BPRS total score. Functional status was evaluated using the Social and Occupational Functioning Assessment Scale (SOFAS). To assess the subjective effects of antipsychotics, the Subjective Wellbeing under Neuroleptic Treatment Scale short form (SWN)[@b19-cpn-17-423] and Drug Attitude Inventory-10[@b20-cpn-17-423] were performed at baseline and at weeks 4, 8, and 12.

Safety assessments included monitoring vital signs, body weight (BW), and body mass index (BMI); a physical examination; AE self-reporting; and scores on the Simpson-Angus Scale, Barnes Akathisia Rating Scale, and Abnormal Involuntary Movement Scale at each visit. Laboratory tests to assess fasting glucose (fasting blood sugar, FBS), total cholesterol (TC), fasting triglyceride (TG), high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, glycated hemoglobin (HbA1c), and prolactin levels were performed at baseline and at week 12.

Statistical Analysis
--------------------

Statistical analyses were performed based on an intent-to-treat analysis, and the data included all patients for whom a baseline and at least one post-baseline measurement were available. The last-observation-carried forward method was applied for endpoint analysis. All subjects who received at least one dose of the study medication were included in the safety analysis.

Categorical variables are presented as absolute numbers and relative frequencies (%) and nominal variables as means and standard deviations. Scores on each psychometric scale and AE scale were analyzed by the Mann-Whitney *U* test, paired *t* test, and repeated measures analysis of variance (RM-ANOVA). The Greenhouse--Geisser correction was used to test for non-sphericity in RM-ANOVA. The chi-square test or Fisher's exact test was used to analyze categorical variables. We also investigated predictors of the response to blonanserin switching by comparing responders (≥50% decrease in the BPRS total score at week 12) and non-responders using the independent *t* test, chi-square test, or Fisher's exact test. Binary logistic regression analysis was conducted, with age, sex, and variables trending toward significance (*p* \< 0.10) in univariate analyses, using response as an independent variable (i.e., responders and non-responders). All statistical tests were two-tailed with a significance level of 0.05. All statistical analyses were conducted using the Statistical Analysis System software package (SAS, version 9.1; SAS Institute, Inc., Cary, NC, USA).

Ethics
------

The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practices. Written informed consent was obtained from all subjects after they had been given an extensive explanation of the nature and procedures of the study. The study protocol was approved by the institutional review or ethics committees at each study site.

RESULTS
=======

Patients and Medications
------------------------

A total of 52 patients were included in the study. The demographic and clinical characteristics of the subjects are presented in [Table 1](#t1-cpn-17-423){ref-type="table"}. Twenty-three patients (44.2%) were treated with a combination of two or more antipsychotics. The antipsychotics previously used were risperidone (n = 31, 59.6%), olanzapine (n = 12, 23.1%), quetiapine (n = 11, 21.2%), haloperidol (n = 10, 19.2%), aripiprazole (n = 6, 11.5%), amisulpride (n = 4, 7.7%), chlorpromazine (n = 4, 7.7%), paliperidone (n = 2, 3.8%), ziprasidone (n = 1, 1.9%), and zotepine (n = 1, 1.9%). The mean chlorpromazine equivalent dose[@b21-cpn-17-423] of these previously used antipsychotics was 773.4 ± 442.7 mg/day at baseline. The mean dose of blonanserin during the entire study period was 17.3 ± 5.2 mg/day, and those at weeks 1, 2, 4, 8, and 12 were 7.3 ± 4.5 mg/day, 15.6 ± 7.0 mg/day, 16.5 ± 6.4 mg/day, 17.4 ± 6.6 mg/day, and 22.1 ± 9.3 mg/day, respectively. Thirty-two (61.5%) patients were treated with benzodiazepines during the study period.

The mean total score on the BPRS decreased significantly from baseline (56.8 ± 9.4) to week 12 (42.1 ± 13.8, *p* \< 0.001) ([Fig. 1](#f1-cpn-17-423){ref-type="fig"}). The difference was significant from week 1 (all *p* \< 0.001). The Clinical Global Impression-Severity score decreased from 4.1 ± 0.7 at baseline (defined as "moderately ill") to 3.4 ± 1.0 (defined as "mildly ill") ([Fig. 1](#f1-cpn-17-423){ref-type="fig"}). The number of responders who showed a ≥ 30% reduction in the BPRS score from baseline to week 12 was 23 (44.2%) ([Fig. 2](#f2-cpn-17-423){ref-type="fig"}). The social functioning, as measured using the SOFAS, and subjective well-being, measured using the SWN, of the patients significantly improved from 39.1 ± 9.8 at baseline to 45.8 ± 8.4 at week 12 (*p* \< 0.001) and from 69.7 ± 14.1 at baseline to 76.7 ± 13.8 at week 12 (*p* \< 0.001), respectively. The attitude toward medication, as measured using the Drug Attitude Inventory-10, also changed significantly during the study period (*p* = 0.019; [Table 2](#t2-cpn-17-423){ref-type="table"}). [Table 3](#t3-cpn-17-423){ref-type="table"} shows a comparison of the characteristics between responders and non-responders. The mean dose of blonanserin used during the study period was significantly higher in responders (20.4 ± 3.7 mg/day) than non-responders (14.7 ± 4.9 mg/day). The rate of taking a blonanserin dose higher than the maintenance dose (high-dose group, \> 16 mg/day) was significantly higher (95.7%, n = 22) among responders than non-responders (51.7%, n = 15). Logistic regression analysis, using age, sex, baseline BPRS and SOFAS scores, and the blonanserin mean dose as covariates, showed that a high mean dose of blonanserin was a significant predictor of the treatment response (odds ratio, 16.744; 95% CI, 1.857--150.983; *p* = 0.012).

Eighteen (34.6%) patients withdrew from the study prematurely: seven (13.5%) withdrew their consent, five (9.6%) were lost to follow-up, four (7.7%) discontinued treatment due to AEs (two cases of akathisia, one case of constipation, and one case of EPS), and two (3.8%) patients violated the protocol. The AEs frequently reported (≥ 3%) during the 12-week study period are listed in [Table 4](#t4-cpn-17-423){ref-type="table"}. A total of 29 (55.8%) patients reported 63 AEs. The severity of all reported AEs was mild (n = 48) or moderate (n = 15). The results of RM-ANOVA showed that the scores on the Simpson-Angus Scale (F = 1.340, *p* = 0.248), Barnes Akathisia Rating Scale (F = 0.906, *p* = 0.477), and Abnormal Involuntary Movement Scale (F = 1.623, *p* = 0.154; [Table 2](#t2-cpn-17-423){ref-type="table"}) did not change significantly during the study period.

Changes in Metabolic Parameters
-------------------------------

In the total study population, HbA1c was the only metabolic parameter that exhibited a significant change from baseline (5.4 ± 0.6%) to the end of the 12-week study period (5.3 ± 0.6%, *p* = 0.021). The serum levels of prolactin and TC also decreased from baseline, but the changes were not statistically significant ([Table 5](#t5-cpn-17-423){ref-type="table"}). When the patients were divided into normal and abnormal subgroups according to their baseline values of metabolic parameters, switching to blonanserin significantly improved BW, TC levels, and prolactin levels in the patients with metabolic abnormalities ([Table 5](#t5-cpn-17-423){ref-type="table"}). In overweight or obese patients (BMI ≥ 23 kg/m^2^, n = 33), switching to blonanserin significantly decreased BW from 75.2 ± 9.3 kg at baseline to 73.5 ± 9.2 kg at week 12 (*p* = 0.006). The decreases in TC (baseline, 236.1 ± 47.6 mg/dl; 12 weeks, 209.9 ± 28.0 mg/dl; *p* = 0.005) and prolactin levels (baseline, 80.0 ± 85.2 ng/ml; 12 weeks, 63.2 ± 88.9 ng/ml; *p* = 0.003) over the study period were also significant in patients with hypercholesterolemia (TC ≥ 200 mg/dl, n = 21) or hyperprolactinemia (prolactin: \> 18 ng/ml in men, \> 29 ng/ml in women; n = 33). FBS and TG levels also decreased from baseline in the abnormal subgroup, but the differences were not statistically significant (*p* = 0.053 and 0.066, respectively).

DISCUSSION
==========

To our knowledge, this is the first study to investigate the impact of switching from other antipsychotics to blonanserin in patients with schizophrenia. In the present study, switching to blonanserin caused a decrease in symptoms of schizophrenia and improvements in function, as measured by the SOFAS, and subjective well-being, measured by the SWN. Moreover, switching to blonanserin also improved HbA1c and some other metabolic and endocrine parameters, including BW, TC levels, and prolactin levels, compared with the baseline values.

The response rate observed in the present study (44.2%) was comparable with the results of previous non-switching studies of blonanserin in schizophrenic patients, which reported response rates of 38% to 49%,[@b11-cpn-17-423],[@b22-cpn-17-423] and switching studies of other antipsychotics, including risperidone, olanzapine, or quetiapine, which reported response rates of approximately 30% to 50%,[@b23-cpn-17-423]--[@b25-cpn-17-423] despite differences in the subject characteristics, measurement scales, and evaluation periods. Moreover, consistent with previous studies of blonanserin, switching to blonanserin was generally well tolerated. There were no serious AEs, and all reported AEs were mild or moderate in severity, with only four (7.7%) patients discontinuing the study due to AEs. As reported in a previous review,[@b26-cpn-17-423] EPS and insomnia were the most frequents AEs. Interestingly, insomnia and emotional arousal, including anxiety, agitation, and excitement, were also reported frequently. These AEs could be due to discontinuation of previous antipsychotics. Discontinuing antipsychotics with strong anticholinergic properties (e.g., olanzapine and quetiapine) may result in insomnia or agitation.[@b27-cpn-17-423] For example, patients switching from olanzapine to risperidone, which has a similar receptor binding profile to that of blonanserin, were reported to experience withdrawal symptoms, including nausea, vomiting, and agitation.[@b28-cpn-17-423]

In the present study, the clinical benefit of switching to blonanserin was associated with a relatively higher blonanserin mean dose. The response rate was significantly higher in the high-dose group (\> 16 mg/day). In a phase III trial,[@b11-cpn-17-423] there appeared to be a numerical dose-response for efficacy when using 2.5, 5, and 10 mg/day blonanserin, but the authors did not compare the differences among dosages. In another study, the occupancy of the striatal dopamine D2 receptor by blonanserin was reported to be 60.8% at 8 mg, 73.4% at 16 mg, and 79.7% at 24 mg.[@b29-cpn-17-423] Therefore, the results from this study were not surprising, in that approximately 70% to 80% of striatal D2 receptor occupancy was required for antipsychotic response.[@b30-cpn-17-423],[@b31-cpn-17-423]

In the present study, there were improvements in HbA1c in the total patient population and in BW and TC in subjects with abnormal metabolic parameter values at baseline. Although little information is available regarding the effects of blonanserin on metabolic parameters, blonanserin has minimal potential for inducing weight gain and metabolic abnormalities due to its low affinity for serotonin 5-HT2C, histamine H1, and muscarinic M1 receptors.[@b8-cpn-17-423] In a meta-analysis of four studies involving 1,080 schizophrenic patients,[@b32-cpn-17-423] there were no significant differences in TC, TG, FBS, or HbA1c levels in patients treated with blonanserin versus antipsychotics, including haloperidol and risperidone. However, blonanserin induced less BW gain compared with risperidone. Furthermore, a recent network meta-analysis indicated that blonanserin was the most BW-neutral antipsychotic, with even less effect on BW than aripiprazole.[@b33-cpn-17-423] As positive effects can be achieved when switching treatment from metabolically disruptive antipsychotics to more BW-neutral antipsychotics,[@b27-cpn-17-423] the results of the present study suggest other benefits of switching to blonanserin from other antipsychotics that have a high to moderate risk of inducing metabolic abnormalities, including olanzapine, quetiapine, and risperidone.

The improvement in hyperprolactinemia, which is associated with sexual dysfunction, bone loss, and increased cancer risks,[@b34-cpn-17-423],[@b35-cpn-17-423] observed in this study was also consistent with previous reports.[@b10-cpn-17-423],[@b36-cpn-17-423],[@b37-cpn-17-423] Blonanserin shows a relatively high brain/plasma concentration ratio (B/P ratio), which is a good biomarker of antipsychotic-induced hyperprolactinemia.[@b29-cpn-17-423],[@b36-cpn-17-423] The B/P ratio indicates the ability of antipsychotics to penetrate the blood-brain barrier, and a high B/P ratio indicates a lower concentration of antipsychotics at the pituitary receptor site than at the cerebral cortex receptor site.[@b38-cpn-17-423] This is thought to be because blonanserin is not a substrate for P-glycoprotein, which actively transports substrates from the brain to the blood across the blood-brain barrier and limits drug entry into the central nervous system.[@b39-cpn-17-423] These findings may explain why the plasma prolactin level was less affected by blonanserin than by other antipsychotics, and support the rationale that blonanserin is a suitable alternative for schizophrenic patients developing antipsychotic-induced hyperprolactinemia.

This study had several limitations, including its small sample size. In addition, this study did not include a control group and was not randomized or blinded. Due to the lack of a control group, the efficacy and tolerability of blonanserin observed in this study cannot be compared with those of other antipsychotic drugs. Due to the small sample size, we could not analyze the effects of previously used antipsychotics to determine whether switching to blonanserin from other antipsychotics would have beneficial effects on psychopathology, tolerability, metabolic, or endocrine parameters. Second, the 2-week tapering-off period applied in our study may be too abrupt to avoid withdrawal symptoms from the previous antipsychotics. Other switching strategies, such as plateau cross-tapering, in which the new antipsychotic is slowly uptitrated with discontinuation of the previous antipsychotic after reaching the therapeutic dosage of the new antipsychotic, or descending taper switch, in which the previous antipsychotic is gradually discontinued and the new one abruptly started at the therapeutic dose, would be more appropriate to exclude potential withdrawal/discontinuing effects of the previous antipsychotic.[@b27-cpn-17-423],[@b40-cpn-17-423] Third, we did not investigate the use of concomitant medications other than benzodiazepines. Therefore, we cannot exclude the possibility that the use of anticholinergics, propranolol, or hypnotics affected the results. In addition, the timing of blonanserin administration was not recorded. As food intake significantly affects the bioavailability of blonanserin,[@b8-cpn-17-423] standardization of the administration timing would allow greater confidence in the results.

In summary, the results of the present study suggested that switching to blonanserin is effective and well-tolerated in patients with schizophrenia who had an insufficient treatment response to other antipsychotics, and it may show additional beneficial effects in terms of improving metabolic and endocrine parameters. Blonanserin appears to be a good treatment option for patients with schizophrenia experiencing an insufficient response to a previous antipsychotic or suffering from metabolic or endocrine AEs. However, the results of the present study are insufficient to derive conclusive clinical recommendations because of the limitations in the methods. Adequately designed, large, double-blind, placebo-controlled, randomized clinical trials are needed to address the usefulness of blonanserin switching in schizophrenic patients.
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###### 

Demographics and clinical characteristics at baseline

  Characteristic                             Data (n = 52)
  ------------------------------------------ ---------------
  Age (yr)                                   46.4 ± 9.9
  Sex, female                                20 (38.5)
  Age of onset (yr)                          29.7 ± 10.0
  Duration of illness (yr)                   16.6 ± 9.2
  Total number of hospitalizations           4.4 ± 4.3
  Previous antipsychotics treatment          
   Monotherapy                               29 (54.9)
   Chlorpromazine equivalent dose (mg/day)   788.6 ± 433.3
  Baseline scores                            
   CGI-S                                     4.1 ± 0.7
   BPRS                                      56.8 ± 9.4
   SOFAS                                     39.0 ± 10.0

Values are presented as mean ± standard deviation or number (%).

CGI-S, Clinical Global Impression-Severity; BPRS, Brief Psychiatric Rating Scale; SOFAS, Social and Occupational Functioning Assessment Scale.

###### 

Changes in SOFAS, DAI-10, SWN, AIMS, SAS and BARS scores from baseline to week 12

  Scale    Baseline      Week 1        Week 2       Week 4        Week 8        Week 12       F value   Significance
  -------- ------------- ------------- ------------ ------------- ------------- ------------- --------- --------------
  SOFAS    39.1 ± 9.8    39.9 ± 10.6   41.9 ± 8.2   43.2 ± 7.7    44.3 ± 7.5    45.8 ± 8.4    13.440    \< 0.001
  DAI-10   5.3 ± 2.5     \-            \-           5.5 ± 2.2     6.1 ± 2.3     5.9 ± 2.2     3.434     0.019
  SWN      69.7 ± 14.1   \-            \-           71.8 ± 14.5   73.6 ± 13.5   76.7 ± 13.8   7.523     \< 0.001
  AIMS     2.2 ± 3.4     2.5 ± 3.6     3.0 ± 4.3    2.9 ± 4.4     2.8 ± 3.9     2.6 ± 3.9     1.623     0.154
  SAS      2.0 ± 2.2     2.1 ± 2.3     2.7 ± 4.2    2.3 ± 2.7     2.1 ± 2.3     2.0 ± 2.3     1.340     0.248
  BARS     0.6 ± 1.3     1.0 ± 1.9     1.0 ± 2.1    0.9 ± 1.7     1.0 ± 1.8     0.8 ± 1.5     0.906     0.477

Values are presented as mean ± standard deviation.

SOFAS, Social and Occupational Functioning Assessment Scale; DAI-10, Drug Attitude Inventory-10; SWN, Subjective Wellbeing under Neuroleptic Scale; AIMS, Abnormal Involuntary Movement Scale; SAS, Simpson-Angus Scale; BARS, Barnes Akathisia Rating Scale; -, not measured.

###### 

Comparisons of characteristics between responders and non-responders

  Characteristic                                Non-responder (n = 29)   Responder (n = 23)   *p* value
  --------------------------------------------- ------------------------ -------------------- -----------
  Age (yr)                                      47.4 ± 9.6               45.0 ± 10.3          0.404
  Sex, female                                   10 (34.5)                10 (43.5)            0.508
  Age of onset (yr)                             31.4 ± 11.0              27.7 ± 8.4           0.198
  Duration of illness (yr)                      16.0 ± 9.7               17.3 ± 8.9           0.612
  Total number of hospitalizations              5.1 ± 4.7                3.6 ± 3.8            0.258
  Previous antipsychotics treatment                                                           
   Monotherapy                                  17 (58.6)                11 (47.8)            0.540
   Chlorpromazine equivalent dose (mg/day)      854.5 ± 472.0            671.1 ± 388.7        0.139
  Baseline scores                                                                             
   CGI-S                                        4.0 ± 0.8                4.2 ± 0.6            0.358
   BPRS                                         55.1 ± 9.3               59.0 ± 9.1           0.138
   SOFAS                                        42.3 ± 8.2               34.8 ± 10.3          0.005
   SWN                                          71.8 ± 12.5              67.1 ± 15.9          0.241
   DAI-10                                       5.2 ± 2.7                5.3 ± 2.2            0.978
  Blonanserin dose during study (mg/day)        14.7 ± 4.9               20.4 ± 3.7           \< 0.001
  Higher than maintenance dose (\> 16 mg/day)   15 (51.7)                22 (95.7)            0.001

Values are presented as mean ± standard deviation or number (%).

CGI-S, Clinical Global Impression-Severity; BPRS, Brief Psychiatric Rating Scale; SOFAS, Social and Occupational Functioning Assessment Scale; SWN, Subjective Wellbeing under Neuroleptic Scale; DAI-10, Drug Attitude Inventory-10.

###### 

Adverse events during study period (≥ 3%)

  Adverse event                                              All adverse events
  ---------------------------------------------------------- --------------------
  Extrapyramidal symptoms (parkinsonism, dystonia, tremor)   12 (23.1)
  Insomnia                                                   10 (19.2)
  Emotional arousal (anxiety, agitation and excitement)      6 (11.5)
  Constipation/abdominal pain                                6 (11.5)
  Cough/upper respiratory infection                          5 (9.6)
  Akathisia                                                  5 (9.6)
  Skin rash/itch                                             4 (7.7)
  Headache                                                   3 (5.8)
  Nausea/vomiting/dyspepsia                                  2 (3.8)

Values are presented as number (%).

###### 

Changes in metabolic parameters over the 12-week study period

  Category by baseline value                       Baseline        Week 12        *p* value
  ------------------------------------------------ --------------- -------------- -----------
  BMI (kg/m^2^)                                                                   
   Total (n = 52)                                  24.8 ± 4.0      24.5 ± 3.6     0.286
   Normal (\< 23, n = 19)                          21.7 ± 2.1      20.8 ± 1.7     0.085
   Overweight/obesity (≥ 23, n = 33)               26.6 ± 3.8      26.6 ± 2.6     0.880
  Weight (kg)                                                                     
   Total (n = 52)                                  68.5 ± 12.5     67.2 ± 12.0    0.113
   Normal (BMI \< 23 kg/m^2^, n = 19)              56.8 ± 8.0      56.1 ± 7.6     0.729
   Overweight/obesity (BMI ≥ 23 kg/m^2^, n = 33)   75.2 ± 9.3      73.5 ± 9.2     0.006
  Fasting glucose (mg/dl)                                                         
   Total (n = 52)                                  102.7 ± 32.9    103.6 ± 28.2   0.774
   Normal (\< 100, n = 31)                         87.6 ± 8.4      94.8 ± 18.2    0.144
   High (≥ 100, n = 21)                            123.6 ± 41.9    115.7 ± 34.8   0.053
  Total cholesterol (mg/dl)                                                       
   Total (n = 52)                                  188.8 ± 53.7    177.6 ± 38     0.081
   Normal (\< 200, n = 31)                         154.5 ± 23.2    154.2 ± 25.0   0.928
   High (≥ 200, n = 21)                            236.1 ± 47.6    209.9 ± 28.0   0.005
  Triglyceride (mg/dl)                                                            
   Total (n = 52)                                  149.6 ± 122.8   140.0 ± 74.8   0.568
   Normal (\< 150, n = 38)                         100.5 ± 26.4    117.0 ± 57.9   0.072
   High (≥ 150, n = 14)                            275.6 ± 176.5   199.3 ± 82.5   0.066
  High-density lipoprotein cholesterol (mg/dl)                                    
   Total (n = 52)                                  50.6 ± 17.1     49.2 ± 15.4    0.378
   Normal (≥ 40 in men, ≥ 50 in women, n = 33)     59.9 ± 14.3     57.7 ± 12.6    0.373
   Low (\< 40 in men, \< 50 in women, n = 19)      35.4 ± 8.0      35.3 ± 7.3     0.936
  Low-density lipoprotein cholesterol (mg/dl)                                     
   Total (n = 52)                                  126.4 ± 64.8    126.6 ± 67.1   0.926
   Normal (\< 130, n = 35)                         91.0 ± 19.6     92.3 ± 19.5    0.693
   High (≥ 130, n = 17)                            186.7 ± 70.8    185.2 ± 78.9   0.345
  Prolactin (ng/ml)                                                               
   Total (n = 52)                                  59.0 ± 78.3     49.1 ± 77.6    0.064
   Normal (≤ 18 in men, ≤ 29 in women, n = 19)     9.5 ± 4.9       15.8 ± 11.5    0.123
   High (\> 18 in men, \> 29 in women, n = 33)     80.0 ± 85.2     63.2 ± 88.9    0.003

Values are presented as mean ± standard deviation.

BMI, body mass index.
